FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2045136965> ?p ?o ?g. }

• W2045136965 endingPage "542" @default.
• W2045136965 startingPage "535" @default.
• W2045136965 abstract "At present, two types of recombinant human interferon (IFN)-β are in clinical use. IFN-β1a is produced in genetically engineered Chinese hamster ovary cells, and its amino acid sequence and glycosylation pattern are identical to those of endogenous human IFN-β. The beneficial effect of IFN-β in multiple sclerosis (MS) probably results from different mechanisms of action, such as a direct effect on plasma cells modulating IgG synthesis, an increase of interleukin (IL)-10 levels, the inhibition of IL-1β and tumour necrosis factor α, the stimulation of IL-1 receptor antagonist production, the inhibition of proliferation of leukocytes, a decreased antigen presentation in microglia, a reduction of T cell migration into the brain by inhibition of the activity of T cell matrix metalloproteinases, and a downregulation of adhesion molecules. IFN-β1a has been shown by several multicenter controlled trials to be effective in relapsing-remitting MS. It reduces relapse rate by 30 – 50%, magnetic resonance imaging signs of disease activity in 30 – 80% and disability progression by 30%. It is also effective in preventing conversion to clinically definite MS when given at the time of a first demyelinating event (i.e., at the very beginning of the clinical disease). No clear evidence of the persistence of the efficacy over the long-term has stood out from a systematic analysis of published trials. A Cochrane review concluded that, in fact, the clinical effect beyond the first year of treatment is not clear. Finally, no efficacy has been shown in secondary progressive or primary progressive MS. However, IFN-β1a is very well tolerated and the most frequent side effects are mild (local skin reaction and flu-like symptoms) and decline in frequency or disappear after the first 3 – 6 months of treatment. Although the optimal frequency between once weekly or multiple weekly administrations is still controversial, all protocols require multiple monthly injections. Some patients might find it hard to cope with such a treatment regimen over the long term. Ongoing trials with new powerful immunomodulatory drugs, such as monoclonal antibodies, that require only monthly or bimonthly parenteral administrations will probably offer a better tolerated treatment option in the near future." @default.
• W2045136965 created "2016-06-24" @default.
• W2045136965 creator A5067420465 @default.
• W2045136965 creator A5067456352 @default.
• W2045136965 creator A5071503464 @default.
• W2045136965 date "2007-03-21" @default.
• W2045136965 modified "2023-09-25" @default.
• W2045136965 title "Interferon-β_1afor the treatment of multiple sclerosis" @default.
• W2045136965 cites W1865315112 @default.
• W2045136965 cites W1965177017 @default.
• W2045136965 cites W1967072617 @default.
• W2045136965 cites W1975995030 @default.
• W2045136965 cites W1982833235 @default.
• W2045136965 cites W1983999022 @default.
• W2045136965 cites W1987745782 @default.
• W2045136965 cites W1997369318 @default.
• W2045136965 cites W1997850414 @default.
• W2045136965 cites W2024061399 @default.
• W2045136965 cites W2026801367 @default.
• W2045136965 cites W2030394626 @default.
• W2045136965 cites W2033175786 @default.
• W2045136965 cites W2034432056 @default.
• W2045136965 cites W2036775477 @default.
• W2045136965 cites W2038316210 @default.
• W2045136965 cites W2038428996 @default.
• W2045136965 cites W2039297765 @default.
• W2045136965 cites W2046354075 @default.
• W2045136965 cites W2047200592 @default.
• W2045136965 cites W2049190400 @default.
• W2045136965 cites W2056736742 @default.
• W2045136965 cites W2065087208 @default.
• W2045136965 cites W2069947868 @default.
• W2045136965 cites W2083770877 @default.
• W2045136965 cites W2086149172 @default.
• W2045136965 cites W2087589796 @default.
• W2045136965 cites W2088205067 @default.
• W2045136965 cites W2088499363 @default.
• W2045136965 cites W2091713192 @default.
• W2045136965 cites W2095666175 @default.
• W2045136965 cites W2102925678 @default.
• W2045136965 cites W2104692290 @default.
• W2045136965 cites W2105477343 @default.
• W2045136965 cites W2112165124 @default.
• W2045136965 cites W2112246282 @default.
• W2045136965 cites W2131709112 @default.
• W2045136965 cites W2137495383 @default.
• W2045136965 cites W2137782187 @default.
• W2045136965 cites W2139367012 @default.
• W2045136965 cites W2148814846 @default.
• W2045136965 cites W2151041276 @default.
• W2045136965 cites W2155441883 @default.
• W2045136965 cites W2164542304 @default.
• W2045136965 cites W2168301183 @default.
• W2045136965 cites W2169098250 @default.
• W2045136965 cites W2413280852 @default.
• W2045136965 cites W2485483395 @default.
• W2045136965 cites W329292291 @default.
• W2045136965 cites W4210933644 @default.
• W2045136965 cites W4253810595 @default.
• W2045136965 doi "https://doi.org/10.1517/14712598.7.4.535" @default.
• W2045136965 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17373904" @default.
• W2045136965 hasPublicationYear "2007" @default.
• W2045136965 type Work @default.
• W2045136965 sameAs 2045136965 @default.
• W2045136965 citedByCount "57" @default.
• W2045136965 countsByYear W20451369652012 @default.
• W2045136965 countsByYear W20451369652013 @default.
• W2045136965 countsByYear W20451369652014 @default.
• W2045136965 countsByYear W20451369652015 @default.
• W2045136965 countsByYear W20451369652017 @default.
• W2045136965 countsByYear W20451369652018 @default.
• W2045136965 countsByYear W20451369652020 @default.
• W2045136965 countsByYear W20451369652021 @default.
• W2045136965 countsByYear W20451369652023 @default.
• W2045136965 crossrefType "journal-article" @default.
• W2045136965 hasAuthorship W2045136965A5067420465 @default.
• W2045136965 hasAuthorship W2045136965A5067456352 @default.
• W2045136965 hasAuthorship W2045136965A5071503464 @default.
• W2045136965 hasConcept C126322002 @default.
• W2045136965 hasConcept C170493617 @default.
• W2045136965 hasConcept C175656101 @default.
• W2045136965 hasConcept C17991360 @default.
• W2045136965 hasConcept C203014093 @default.
• W2045136965 hasConcept C2776036978 @default.
• W2045136965 hasConcept C2776178377 @default.
• W2045136965 hasConcept C2778690821 @default.
• W2045136965 hasConcept C2780640218 @default.
• W2045136965 hasConcept C2780841837 @default.
• W2045136965 hasConcept C2910198813 @default.
• W2045136965 hasConcept C2994247566 @default.
• W2045136965 hasConcept C71924100 @default.
• W2045136965 hasConceptScore W2045136965C126322002 @default.
• W2045136965 hasConceptScore W2045136965C170493617 @default.
• W2045136965 hasConceptScore W2045136965C175656101 @default.
• W2045136965 hasConceptScore W2045136965C17991360 @default.
• W2045136965 hasConceptScore W2045136965C203014093 @default.
• W2045136965 hasConceptScore W2045136965C2776036978 @default.
• W2045136965 hasConceptScore W2045136965C2776178377 @default.

• next